Biohaven Ltd. (BHVN) earnings date

NYSE · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 42 days, typically, give or take 12 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Oct 29, 2026after close 29 8-K
Q2 FY2026Mon, Aug 10, 2026after close 41 8-K
Q1 FY2026Mon, May 4, 2026after close 34 8-K
Q4 FY2025Mon, Mar 2, 2026after close 61 8-K
Q3 FY2025Mon, Nov 10, 2025before open 41 8-K
Q2 FY2025Mon, Aug 11, 2025after close 42 8-K
Q1 FY2025Mon, May 12, 2025after close 42 8-K
Q4 FY2024Mon, Mar 3, 2025after close 62 8-K

What they guided beta

Q3 FY2026 "On track to initiate the pivotal Phase 3 trial of BHV-1400, a TRAP™ extracellular degrader targeting galactose-deficient IgA1 (Gd-IgA1), in IgA nephropathy (IgAN) during 4Q 2026." exhibit
Q3 FY2026 "We are making meaningful progress with the first degraders from our MoDE and TRAP platforms, with BHV-1300 now in a pivotal Phase 3 trial in Graves’ disease and BHV-1400 expected to begin its next stage of clinical development in IgA nephropathy in the second half of 2026." exhibit
Q3 FY2026 "As a result of the amended study design, we now anticipate topline data from the monotherapy and combination therapy portions of the trial in 2H 2027." exhibit
Q3 FY2026 "Topline results for Phase 2/3 study expected in 2H 2026." exhibit
Q3 FY2026 "Phase 2 study in obesity remains ongoing with planned addition of GLP-1 combination cohort; topline data expected in 2H 2027." exhibit
Q2 FY2026 "Topline data expected during 2H 2026." exhibit
Q2 FY2026 "A pivotal study is expected to initiate in 2H 2026." exhibit
Q2 FY2026 "Topline results from the Phase 2/3 RISE3 trial in focal epilepsy are expected during 2H 2026." exhibit
Q2 FY2026 "Continued advancement of Biohaven's oncology portfolio: In July 2026, the Company announced that new data on BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC) using a novel topoisomerase I (TopoIx) payload, will be presented at the ESMO Congress 2026." exhibit
Q2 FY2026 "Reported first-in-human (FIH) dosing of oral PKM2 modulator, BHV-8100, targeting metabolic restoration and immunomodulation: In June 2026, the Company announced the initiation of FIH dosing for BHV-8100, its oral, brain-penetrant pyruvate kinase M2 isoform (PKM2) modulator." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/BHVN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/BHVN

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

BHVN earnings date badge

HTML

<a href="https://veritasdata.dev/company/BHVN/"><img src="https://veritasdata.dev/embed/BHVN.svg" alt="BHVN earnings date" width="240" height="56"></a>

Markdown

[![BHVN earnings date](https://veritasdata.dev/embed/BHVN.svg)](https://veritasdata.dev/company/BHVN/)

Script

<script async src="https://veritasdata.dev/embed/BHVN.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/BHVN"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.